HPV prevalence among women from the CARE Project and the NHANES.

<p><i>Note.</i> Table reports percents and 95% confidence intervals in parentheses. HPV  =  human papillomavirus, CARE  =  Community Awareness Resources Education, NHANES  =  National Health and Nutrition Examination Survey.</p>a<p>Estimates from the NHANES are for non-Hispanic white women <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0074276#pone.0074276-Hariri1" target="_blank">[4]</a>, since 93.9% of women from the CARE Project were non-Hispanic white.</p>b<p>Included HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 64, 66, 67, 68, 69, 70, 73, 82, and IS39 <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0074276#pone.0074276-Hariri1" target="_blank">[4]</a>.</p>c<p>Included HPV types 6, 11, 40, 42, 54, 55, 61, 62, 71, 72, 81, 83, 84, and 89 <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0074276#pone.0074276-Hariri1" target="_blank">[4]</a>.</p

Prevalence of HPV types among women from the CARE Project.

<p><i>Note.</i> Table reports n (%). HPV  =  human papillomavirus, CARE  =  Community Awareness Resources Education.</p>a<p>High- and low-risk classification scheme is the same as a recent national study that analyzed data from the National Health and Nutrition Examination Survey (NHANES) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0074276#pone.0074276-Hariri1" target="_blank">[4]</a>.</p

Detection of any HPV type among women from the CARE Project (n = 1116).

<p><i>Note.</i> Totals may be less than stated sample size due to missing data. The multivariable model included data on 814 women due to missing data on correlates. The multivariable model did not include variables with dashes (--). HPV  =  human papillomavirus, CARE  =  Community Awareness Resources Education, OR  =  odds ratio, CI  =  confidence interval, ref.  =  referent group, STI  =  sexually transmitted infection.</p>*<p><i>p</i><0.05, **<i>p</i><0.001.</p

Characteristics of women from the CARE Project (n = 1116).

<p><i>Note.</i> Totals may be less than stated sample size due to missing data. Percents may not sum to 100% due to rounding. CARE  =  Community Awareness Resources Education, HPV  =  human papillomavirus, STI  =  sexually transmitted infection.</p

The <i>KRAS-</i>variant is significantly associated with developing ovarian cancer post-menopausally compared to pre-menopausally.

<p>The <i>KRAS-</i>variant is significantly associated with developing ovarian cancer post-menopausally compared to pre-menopausally.</p

The <i>KRAS-</i>variant is significantly associated with uninformative breast and ovarian cancer patients.

<p>The <i>KRAS-</i>variant is significantly associated with uninformative breast and ovarian cancer patients.</p

The <i>KRAS</i>-variant is significantly associated with the risk of developing additional cancers beyond breast and ovarian cancer.

<p>The <i>KRAS</i>-variant is significantly associated with the risk of developing additional cancers beyond breast and ovarian cancer.</p

Prevalence of the <i>KRAS-</i>variant in uninformative patients.

<p>Prevalence of the <i>KRAS-</i>variant in uninformative patients.</p

Candidate enriched gene sets for differentially methylated genes associated with HPV status.

<p>Candidate enriched gene sets for differentially methylated genes associated with HPV status.</p

Kaplan-Meier survival curves depicting three year survival for each of the six clusters identified via unsupervised hierarchical cluster analysis.

<p>Kaplan-Meier survival curves depicting three year survival for each of the six clusters identified via unsupervised hierarchical cluster analysis.</p